Silibinin attenuates MPP+-induced neurotoxicity in the substantia nigra in vivo

Journal of Medicinal Food

Volumn 17, Issue 5, 2014, Pages 599-605

  Jung, Un Ju ^a   Jeon, Min Tae ^a   Choi, Myung Sook ^a   Kim, Sang Ryong ^a  

^a Kyungpook National University   (South Korea)

Author keywords

anti inflammation; neurodegeneration; neuroprotection; Parkinson's disease; silibinin

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; SILIBININ; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NEUROPROTECTIVE AGENT; SILYMARIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; FEMALE; IN VIVO STUDY; INFLAMMATION; MICROGLIA; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; METABOLISM; NERVE DEGENERATION; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TOXICITY;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INFLAMMATION; INTERLEUKIN-1BETA; MICROGLIA; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE II; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SILYMARIN; SUBSTANTIA NIGRA; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE 3-MONOOXYGENASE;

EID: 84900543625     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2013.2926     Document Type: Article

References (33)

1. Savitt JM, Dawson VL, Dawson TM: Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006; 116: 1744-1754.
2. Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY, et al.: Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharm 2011; 60: 963-974.
3. Kim SR, Chen X, Oo TF, Kareva T, Yarygina O, Wang C, et al.: Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann Neurol 2011; 70: 110-120.
4. Kim SR, Kareva T, Yarygina O, Kholodilov N, Burke RE: AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth. Mol Ther 2012; 20: 275-286.
5. Liu B: Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J 2006; 8: E606-621.
6. Del Zoppo GJ, Milner R, Mabuchi T, Hung S, Wang X, Berg GI, et al.: Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke 2007; 38: 646-651.
7. Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A: Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int Rev Neurobiol 2007; 82: 235-246.
8. Kim SR, Chung ES, Bok E, Baik HH, Chung YC, Won SY, et al.: Prothrombin kringle-2 induces death of mesencephalic dopaminergic neurons in vivo and in vitro via microglial activation. J Neurosci Res 2010; 88: 1537-1548.
9. Storch A, Ludolph AC, Schwarz J: Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J Neural Transm 2004; 111: 1267-1286.
10. Obata T: Nitric oxide and MPP+ -induced hydroxyl radical generation. J Neural Transm 2006; 113: 1131-1144.
11. Block ML, Hong JS: Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog Neurolbiol 2005; 76: 77-98.
12. Wang T, Zhang W, Pei Z, Block M, Wilson B, Reece JM, et al.: Reactive microgliosis participates in MPP+ -induced dopaminergic neurodegeneration: role of 67kDa laminin receptor. FASEB J 2006; 20: 906-915.
13. Miwa H, Kubo T, Morita S, Nakanishi I, Kondo T: Oxidative stress and microglial activation in substantia nigra following striatal MPP+ . Neuroreport 2004; 15: 1039-1044.
14. Kim HG, Ju MS, Ha SK, Lee H, Lee H, Kim SY, et al.: Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine- induced neuroinflammation in vitro and in vivo. Biol Pharm Bull 2012; 35: 1287-1294.
15. Wang MH, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, et al.: Silymarin protects dopaminergic neurons against lipopolysaccharide- induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 2002; 16: 2103-2112.
16. Baluchnejadmojarad T, Roghani M, Mafakheri M: Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-Parkinsonian rat: involvement of estrogen receptors and oxidative stress. Neurosci Lett 2010; 480: 206-210.
17. Wang C, Wang Z, Zhang X, Zhang X, Dong L, Xing Y, et al.: Protection by silibinin against experimental ischemic stroke: upregulated pAkt, pmTOR, HIF-1a and Bcl-2, down-regulated Bax, NF-jB expression. Neurosci Lett 2012; 529: 45-50.
18. Prabu SM, Muthumani M: Silibinin ameliorates arsenic induced nephrotoxicity by abrogation of oxidative stress, inflammation and apoptosis in rat. Mol Biol Rep 2012; 39: 11201-11216.
19. Lu P, Mamiya T, Lu LL, Mouri A, Zou L, Nagai T, Hiramatsu M, et al.: Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br J Pharmacol 2009; 157: 1270-1277.
20. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA, 1998.
21. Park ES, Kim SR, Jin BK: Transient receptor potential vanilloid subtype 1 contributes to mesencephalic dopaminergic neuronal survival by inhibiting microglia-originated oxidative stress. Brain Res Bull 2012; 89: 92-96.
22. Bournival J, Plouffe M, Renaud J, Provencher C, Martinoli MG: Quercetin and sesamin protect dopaminergic cells from MPP+ - induced neuroinflammation in a microglial (N9)-neuronal (PC12) coculture system. Oxid Med Cell Longev 2012; 2012: 921941.
23. Yu HH, Wu FL, Lin SE, Shen LJ: Recombinant arginine deiminase reduces inducible nitric oxide synthase iNOS-mediated neurotoxicity in a coculture of neurons and microglia. J Neurosci Res 2008; 86: 2963-2972.
24. Colton CA, Vitek MP, Wink DA, Xu Q, Cantillana V, Previti ML, et al.: NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103: 12867-12872.
25. Block ML, Hong JS: Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005; 76: 77-98.
26. Liberatore GT, Jackson-Lewis V, Vukosavic S, MandirAS, VilaM, McAuliffe WG, et al.: Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999; 5: 1403-1409.
27. Muroyama A, Fujita A, Lv C, Kobayashi S, Fukuyama Y, Mitsumoto Y: Magnolol protects againstMPTP/MPP(+)-induced toxicity via inhibition of oxidative stress in in vivo and in vitro models of Parkinson's disease. Parkinsons Dis 2012; 2012: 985157.
28. Blesa J, Phani S, Jackson-Lewis V, Przedborski S: Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012; 2012: 845618.
29. Yokoyama H, Kuroiwa H, Yano R, Araki T: Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci 2008; 29: 293-301.
30. Gao JP, Sun S, Li WW, Cai DF: Triptolide protects against 1- methyl-4-phenyl pyridium-induced dopaminergic neurotoxicity in rats: implication for immunosuppressive therapy in parkinson's disease. Neurosci Bulls 2008; 24: 133-142.
31. Hung SY, Liou HC, Kang KH, Wu RM, Wen CC, Fu WM: Overexpression of heme oxygenase-1 protects dopaminergic neurons against 1-methyl-4-phenylpyridinium- induced neurotoxicity. Mol Pharmacol 2008; 74: 1564-1575.
32. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al.: Blockade microglial activation is neuroprotective in the 1-methyl-4phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002; 22: 1763-1771.
33. Malek R, Borowicz KK, Jargiello M, Czuczwar SJ: Role of nuclear factor kappa B in the central nervous system. Pharmacol Rep 2007; 59: 25-33.